Vnitr Lek 2025, 71(6):389-393 | DOI: 10.36290/vnl.2025.073

Evinacumab: a therapeutic agent for homozygous familial hypercholesterolemia

Vladimír Blaha
III. interní gerontometabolická klinika Lékařské fakulty UK a Fakultní nemocnice, Hradec Králové

Homozygous familial hypercholesterolemia (HoFH) is a severe genetic disorder characterized by extremely high levels of LDL cholesterol and early development of atherosclerosis. Despite combined lipid-lowering therapy, the vast majority of patients fail to achieve target LDL-C levels. Evinacumab, a fully human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), represents a novel therapeutic option. This article summarizes the mechanism of action, clinical evidence, and practical aspects of evinacumab administration in patients with HoFH.

Keywords: homozygous familial hypercholesterolemia, LDL cholesterol, cardiovascular disease, lipid-lowering therapy, evinacumab.

Accepted: September 21, 2025; Published: October 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Blaha V. Evinacumab: a therapeutic agent for homozygous familial hypercholesterolemia. Vnitr Lek. 2025;71(6):389-393. doi: 10.36290/vnl.2025.073.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bruckert E. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement. Atheroscler Suppl. 2014;15(2):2632. Go to original source... Go to PubMed...
    2. Raal FJet al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(8):711720. Go to original source... Go to PubMed...
    3. Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J Lipid Res. 2021;62:100060. Go to original source... Go to PubMed...
    4. Hegele RA, Tsimikas S. LipidLowering Agents. Circ Res. 2019;124(3):386404. Go to original source... Go to PubMed...
    5. Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018;277:483492. Go to original source... Go to PubMed...
    6. Stefanutti Cet al. Realworld experience of longterm efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis. J Clin Lipidol. 2024;18(5):e817e824. Go to original source... Go to PubMed...
    7. Cuchel Met al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):22772291. Go to original source... Go to PubMed...
    8. Goldberg ACet al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3):133140. Go to original source... Go to PubMed...
    9. Raal FJet al. The LongTerm Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. JACC Adv. 2023;2(9):100648. Go to original source... Go to PubMed...
    10. Wilkinson MJet al. RealWorld Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective. Arterioscler Thromb Vasc Biol. 2025;19(9):538. Go to original source... Go to PubMed...
    11. Rosenson Ret al. The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No LowDensity Lipoprotein Receptor Activity. J Clin Lipidol. 2020;14(4):552. Go to original source...
    12. Gaudet Det al. Evinacumab in homozygous familial hypercholesterolaemia: longterm safety and efficacy. Eur Heart J. 2024;45(27):24222434. Go to original source... Go to PubMed...
    13. Béliard Set al. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2024;44(6):14471454. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.